Show simple item record

dc.contributor.authorCertain, Laura K.
dc.contributor.authorWay, Jeffrey C.
dc.contributor.authorPezone, Matthew J.
dc.contributor.authorCollins, James J.
dc.date.accessioned2018-08-27T19:20:29Z
dc.date.available2018-08-27T19:20:29Z
dc.date.issued2017-08
dc.date.submitted2017-05
dc.identifier.issn1931-3128
dc.identifier.urihttp://hdl.handle.net/1721.1/117562
dc.description.abstractSynthetic biology has focused on engineering microbes to synthesize useful products or to serve as living diagnostics and therapeutics. Here we utilize a host-derived Escherichia coli strain engineered with a genetic toggle switch as a research tool to examine in vivo replicative states in a mouse model of chronic infection, and to compare in vivo and in vitro bacterial behavior. In contrast to the effect of antibiotics in vitro, we find that the fraction of actively dividing bacteria remains relatively high throughout the course of a chronic infection in vivo and increases in response to antibiotics. Moreover, the presence of non-dividing bacteria in vivo does not necessarily lead to an antibiotic-tolerant infection, in contrast to expectations from in vitro experiments. These results demonstrate the utility of engineered bacteria for querying pathogen behavior in vivo, and the importance of validating in vitro studies of antibiotic effects with in vivo models. Using Escherichia coli engineered with a genetic toggle switch, Certain et al. demonstrate ongoing bacterial replication in a mouse model of chronic infection, even with antibiotic treatment. This finding runs contrary to the expectation that antibiotics preferentially eliminate actively dividing bacteria and highlights the in vivo utility of synthetic biology.en_US
dc.description.sponsorshipDefense Threat Reduction Agency (DTRA) (Grant HDTRA1-15-1-0051)en_US
dc.publisherElsevier BVen_US
dc.relation.isversionofhttp://dx.doi.org/10.1016/J.CHOM.2017.08.001en_US
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivs Licenseen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.sourceElsevieren_US
dc.titleUsing Engineered Bacteria to Characterize Infection Dynamics and Antibiotic Effects In Vivoen_US
dc.typeArticleen_US
dc.identifier.citationCertain, Laura K. et al. “Using Engineered Bacteria to Characterize Infection Dynamics and Antibiotic Effects In Vivo.” Cell Host & Microbe 22, 3 (September 2017): 263–268 © 2017 The Authorsen_US
dc.contributor.departmentInstitute for Medical Engineering and Scienceen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biological Engineeringen_US
dc.contributor.mitauthorCollins, James J.
dc.relation.journalCell Host & Microbeen_US
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2018-08-27T18:44:04Z
dspace.orderedauthorsCertain, Laura K.; Way, Jeffrey C.; Pezone, Matthew J.; Collins, James J.en_US
dspace.embargo.termsNen_US
dc.identifier.orcidhttps://orcid.org/0000-0002-5560-8246
mit.licensePUBLISHER_CCen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record